NEUROBIOLOGICAL TECHNOLOGIES INC /CA/
10QSB, EX-27, 2000-11-14
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Previous: NEUROBIOLOGICAL TECHNOLOGIES INC /CA/, 10QSB, EX-10.23, 2000-11-14
Next: PADCO ADVISORS INC /MD NEW/, 13F-HR, 2000-11-14



<TABLE> <S> <C>

 <ARTICLE>                                5
 <LEGEND>THE SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION
         EXTRACTED FROM BALANCE SHEET AND INCOME STATEMENTS
         DATED 9/30/00 AND IS QUALIFIED IN ITS ENTIRETY BY
         REFERENCE TO SUCH FINANCIAL STATEMENTS
 </LEGEND>
 <RESTATED>
 <CIK>                                    0000918112
 <NAME>                                   PACIFIC FINANCIAL PRINTING
 <MULTIPLIER>                             1
 <CURRENCY>                               U.S. DOLLARS

 <S>                                      <C>
 <PERIOD-TYPE>                            3-MOS
 <FISCAL-YEAR-END>                        JUN-30-2001
 <PERIOD-START>                           JUL-1-2000
 <PERIOD-END>                             SEP-30-2000
 <EXCHANGE-RATE>                          1
 <CASH>                                   3,786,266
 <SECURITIES>                             3,718,190
 <RECEIVABLES>                            0
 <ALLOWANCES>                             0
 <INVENTORY>                              0
 <CURRENT-ASSETS>                         7,553,716
 <PP&E>                                   344,751
 <DEPRECIATION>                           299,363
 <TOTAL-ASSETS>                           8,310,669
 <CURRENT-LIABILITIES>                    536,003
 <BONDS>                                  0
                     0
                               1,091,000
 <COMMON>                                 42,686,817
 <OTHER-SE>                               (36,003,151)
 <TOTAL-LIABILITY-AND-EQUITY>             8,310,669
 <SALES>                                  0
 <TOTAL-REVENUES>                         0
 <CGS>                                    0
 <TOTAL-COSTS>                            0
 <OTHER-EXPENSES>                         764,268
 <LOSS-PROVISION>                         0
 <INTEREST-EXPENSE>                       (145,897)
 <INCOME-PRETAX>                          (618,371)
 <INCOME-TAX>                             0
 <INCOME-CONTINUING>                      (618,371)
 <DISCONTINUED>                           0
 <EXTRAORDINARY>                          0
 <CHANGES>                                0
 <NET-INCOME>                             (618,317)
 <EPS-BASIC>                              (0.04)
 <EPS-DILUTED>                            (0.04)


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission